ESTRO 2024 - Abstract Book

S1719

Clinical - Lung

ESTRO 2024

3. Yegya-Raman N, Wang K, Kim S, Reyhan M, Deek MP, Sayan M, et al. Dosimetric Predictors of Symptomatic Cardiac Events After Conventional-Dose Chemoradiation Therapy for Inoperable NSCLC. J Thorac Oncol [Internet]. 2018 Oct 1 [cited 2022 Oct 28];13(10):1508 – 18. Available from: https://pubmed.ncbi.nlm.nih.gov/29883836/ 4. Speirs CK, DeWees TA, Rehman S, Molotievschi A, Velez MA, Mullen D, et al. Heart Dose Is an Independent Dosimetric Predictor of Overall Survival in Locally Advanced Non-Small Cell Lung Cancer. J Thorac Oncol [Internet]. 2017 Feb 1 [cited 2022 Dec 8];12(2):293 – 301. Available from: https://pubmed.ncbi.nlm.nih.gov/27743888/

2159

Digital Poster

SBRT versus RFA: Baseline characteristics and outcomes in patients with lung metastases

Daniel Tong 1 , Jennifer Pang 2 , Nicos Fotiadis 3 , Laura Satchwell 4 , Zayn Rajan 4 , Mohammad Emarah 1,5 , Usman Bashir 6 , Derfel ap Dafydd 7 , James McCall 3 , David Cunningham 8 , Merina Ahmed 1 1 Royal Marsden Hospital, Lung, Sutton, United Kingdom. 2 Maidstone and Tunbridge Wells NHS Trust, Lung, Maidstone, United Kingdom. 3 Royal Marsden Hospital, Interventional Radiology, London, United Kingdom. 4 Royal Marsden Hospital, Medical Statistics, London, United Kingdom. 5 Alexandria University, Clinical Oncology, Alexandria, Egypt. 6 Barts and London Hospitals, Radiology, London, United Kingdom. 7 Royal Marsden Hospital, Radiology, London, United Kingdom. 8 Royal Marsden Hospital, Gastrointestinal and Lymphoma, London, United Kingdom

Purpose/Objective:

To determine any differences between baseline characteristics and outcomes of patients treated with radiofrequency ablation (RFA) or stereotactic radiotherapy (SBRT) for lung metastases.

Material/Methods:

Retrospective review of all consecutive patients treated at Royal Marsden Hospital with RFA or SBRT for lung metastases between November 2011 and December 2019. 106 patients treated with RFA and 70 treated with SBRT with at least 3 months’ of follow up were included in this study. Baseline characteristics, local control, survival, and adverse events were compared. Imaging were reviewed by independent consultant radiologists. Local progression, distant progression and overall survival were estimated using the Kaplan Meier method. Univariable analysis was carried out using Cox regression. Following this, a multivariable model was constructed using a backwards elimination stepwise procedure, with a p-value cutoff of 0.05.

Results:

Median follow up was 29.7 and 32.2 months for SBRT and RFA patients, respectively. Tumours treated with SBRT were larger: median size 16.5 mm vs 10 mm. 91.4% of SBRT patients were oligometastatic at the time of treatment,